Investor FAQ

Home / Investor Relations / Investor FAQ



This FAQ is for general information about Cellular Biomedicine (“CBMG” or the “Company”).

This information was last updated on June 1, 2017 and should be considered current as of that date.

When was CBMG established?
CBMG was established in 2009.
Where is CBMG located?
CBMG has offices in Cupertino, California. We also have offices across the world, including in Hong Kong, R&D facilities in Wuxi, China, and Beijing, China and an international-standard protocol-compliant manufacturing facility in Shanghai, China.
What are CBMG’s products?
We are developing our business on two cellular therapeutic platforms: Immuno-Oncology and Stem Cell Regenerative Medicine.
Where are CBMG’s target markets?
CBMG’s primary target market is Greater China. We are also expanding into the global market by seeking international strategic collaborations in the U.S. and abroad.
What are CBMG’s ticker symbol, exchange, and CUSIP?
The ticker symbol is NASDAQ: CBMG, and the CUSIP number is 15117P102.
How many shares of CBMG are outstanding?
As of April 31, 2017, there were 14,290,668 shares of common stock, par value $.001 per share issued and outstanding.
What is CBMG’s fiscal year and corresponding quarter-end dates
CBMG operates on a fiscal year that runs from January 1 to December 31. Quarter-­ends are: March 31 (Q1), June 30 (Q2), and September 30 (Q3
How can I invest in CBMG?
You can purchase CBMG common stock through a registered brokerage or stock purchase service provider of your choice. You are unable to buy stock directly from CBMG.
Who is CBMG’s IR contact?
Sarah Kelly, Director of Corporate Communications, CBMG Phone: +1 408-973-7884 (USA) or +86 21 5406 9990 (China) Email:
Who is CBMG’s transfer agent?
The Company’s transfer agent and registrar for the common stock is Corporate Stock Transfer, Inc. located in Denver, Colorado.